---

Acute Promyelocytic Leukemia (APL / AML-M3) - Complete Clinical Note

---

1. DEFINITION AND OVERVIEW

• Harrison's Principles of Internal Medicine, 22E (2025), p.877
• Henry's Clinical Diagnosis and Management by Laboratory Methods

---

2. ETIOLOGY AND PATHOGENESIS

2.1 Molecular Basis

• Blocks normal retinoic acid receptor signaling
• Recruits nuclear co-repressors (NCoR, SMRT, HDAC complexes) causing transcriptional repression of myeloid differentiation genes
• Arrests maturation at the promyelocyte stage
• Promotes self-renewal of malignant promyelocytes
• Prevents apoptosis via aberrant epigenetic silencing

2.2 Variant Translocations (Rare, ~1-2%)

Clinically critical: PLZF-RARA variants are ATRA-resistant and must be identified early.

2.3 Risk Classification (Sanz Score - PETHEMA)

• Standard-risk: WBC ≤10,000/μL
• High-risk: WBC >10,000/μL

---

3. CLINICAL FEATURES

3.1 Presenting Symptoms

• Bleeding diathesis (most distinctive): ecchymoses, petechiae, gingival bleeding, menorrhagia, epistaxis, CNS hemorrhage
• Fatigue, pallor (anemia)
• Fever (infection or leukemic fever)
• Bone pain
• Hepatosplenomegaly (less common than other AMLs)
• Notably absent: lymphadenopathy is rare

3.2 Morphologic Subtypes

The microgranular variant is a trap - morphology can be mistaken for monocytic leukemia but granules are abundant on electron microscopy. FISH/PCR is mandatory.

---

4. DIFFERENTIAL DIAGNOSIS

---

5. LABORATORY DIAGNOSIS

5.1 Complete Blood Count

5.2 Coagulation Profile (Critical in APL)

Mechanism: Promyelocyte granules contain tissue factor, cancer procoagulant, and annexin II (promotes plasminogen → plasmin conversion), driving simultaneous DIC + hyperfibrinolysis.

5.3 Bone Marrow Examination

• Aspirate: >20% hypergranular promyelocytes; Auer rods/faggots; marrow usually hypercellular
• Biopsy: Not always required if aspirate diagnostic
• Cytochemistry: MPO strongly positive; NSE negative (unlike monocytic)

5.4 Immunophenotype (Flow Cytometry)

HLA-DR negativity with CD34 negativity and strong CD13/33 in a bleeding patient = start ATRA NOW.

5.5 Cytogenetics and Molecular

RT-PCR isoform matters: bcr3 (short) correlates with higher WBC and microgranular variant. Also critical for MRD monitoring.

5.6 Chemistry Panel

• LDH: elevated (tumor burden)
• Uric acid: elevated
• Creatinine: check baseline (ATO nephrotoxic)
• Electrolytes: check K, Mg (QTc risk with ATO)
• LFTs: baseline (both ATRA and ATO can be hepatotoxic)
• ECG: baseline QTc before starting ATO (prolongation is contraindication to ATO)

---

6. MANAGEMENT

6.1 EMERGENCY MANAGEMENT (Before Genetics Are Confirmed)

• ATRA 45 mg/m²/day orally in two divided doses
• Aggressive transfusion support:
  • Platelets: keep >50 × 10⁹/L (>30 × 10⁹/L minimum)
  • Cryoprecipitate/FFP: keep fibrinogen >150 mg/dL (>100 mg/dL minimum)
  • Correct coagulopathy aggressively - hemorrhagic death kills before therapy works
• AVOID heparin (worsens hemorrhage)
• AVOID lumbar puncture until coagulopathy corrected

6.2 INDUCTION THERAPY

Standard-Risk APL (WBC ≤10,000/μL) - CURRENT STANDARD OF CARE

High-Risk APL (WBC >10,000/μL)

• ATRA 45 mg/m² + ATO 0.15 mg/kg/day + idarubicin 12 mg/m² IV on days 1 and 3
• Followed by 4 cycles of ATRA-ATO consolidation (no further anthracycline)

• ATRA 45 mg/m²/day + idarubicin 12 mg/m² IV on days 2, 4, 6, 8
• Followed by anthracycline-based consolidation + 2 years ATRA maintenance

The 2025 APOLLO Trial (Platzbecker et al., JCO 2025, PMID 40825164) demonstrated 2-year EFS of 88% with ATRA-ATO + minimal idarubicin vs. 71% with ATRA-CHT (AIDA) in high-risk APL, supporting ATRA-ATO extension to high-risk disease.

If Contraindications to ATO

• Prolonged QTc (>500 ms after correction)
• Severe hepatic impairment
• Uncontrolled electrolyte abnormalities

6.3 DIFFERENTIATION SYNDROME (DS) - MANAGEMENT

• Mild DS: Start dexamethasone 10 mg IV every 12 hours
• Moderate/severe DS: Dexamethasone + temporary hold of ATRA and/or ATO
• Continue dexamethasone until symptoms resolve (minimum 3 days)
• Cytoreduction with hydroxyurea if WBC rising rapidly

6.4 CONSOLIDATION THERAPY

• 4 consolidation cycles (each cycle = 4 weeks on/4 weeks off)
• ATRA 45 mg/m²/day × 2 weeks every 4 weeks for 7 cycles total
• ATO 0.15 mg/kg/day × 5 days/week × 4 weeks per cycle (4 cycles total)

• 4 cycles of ATRA + ATO (0.15 mg/kg/day × 5 days/week × 4 weeks per cycle)
• No additional anthracycline consolidation needed

6.5 MOLECULAR REMISSION MONITORING (MRD)

• Persistent/rising PCR after consolidation = relapse signal → act before hematologic relapse
• Sensitivity of PCR: 10⁻⁴ to 10⁻⁵ (one leukemic cell per 10,000-100,000 normal cells)

---

7. RELAPSED APL

7.1 Salvage with ATO

7.2 Gemtuzumab Ozogamicin (GO)

• Anti-CD33 antibody-drug conjugate
• Used in combination or alone in relapsed APL
• Achieves molecular CR in patients who have received both ATRA and ATO
• Particularly valuable as bridge to transplant

7.3 Transplantation in Relapsed APL

• PCR-positive at time of transplant (GVL benefit needed)
• Third or later relapse
• High-risk features not achieving molecular CR

---

8. LANDMARK CLINICAL TRIALS - CHRONOLOGICAL

Era 1: Discovery of ATRA (1987-1997)

• First clinical use of ATRA in 24 APL patients - CR rate 96%
• Revolutionized APL from a fatal to a curable disease
• Established that pharmacologic doses of ATRA cause terminal differentiation of leukemic promyelocytes

• Randomized ATRA → chemotherapy vs. concurrent ATRA + chemotherapy vs. chemotherapy alone
• Established ATRA + chemotherapy as standard of care
• 2-year DFS: ATRA → chemo 62%, concurrent 79%, chemo 50%

• ATRA + idarubicin (without cytarabine) as induction
• CR ~95%, OS at 5 years ~75-80%
• Established AIDA as the gold standard chemotherapy-based regimen for APL

Era 2: Arsenic Trioxide (1996-2010)

• First systematic clinical trial of ATO in relapsed APL
• CR rate ~85% with ATO monotherapy in relapsed/refractory APL
• Launched the ATO revolution

• ATO + ATRA pilot studies demonstrated synergistic efficacy

• ATRA + ATO ± gemtuzumab in newly diagnosed APL, all risk groups
• CR 92%, 3-year OS 85% - first suggestion that chemotherapy could be eliminated

Era 3: Chemotherapy-Free Regimens (2013-2017) - PARADIGM SHIFT

• Phase III RCT: ATRA + ATO vs. ATRA + idarubicin-chemotherapy in low/intermediate-risk APL (WBC ≤10 × 10⁹/L)
• n = 156 patients (80 ATRA-ATO, 79 ATRA-CHT)
• CR: 100% ATRA-ATO vs. 95% ATRA-CHT (P=0.12)
• 2-year EFS: 97% vs. 86% (P=0.02 for superiority of ATRA-ATO)
• OS at 2 years: 99% vs. 91% (P=0.02)
• Less hematologic toxicity, fewer infections with ATRA-ATO
• Established ATRA + ATO as the new standard of care for non-high-risk APL

• Confirmed and extended: 50-month EFS 97.3% vs. 80% (P<0.001)
• CIR: 1.9% vs. 13.9% (P=0.0013)
• OS: 99.2% vs. 92.6% (P=0.0073)
• No maintenance needed in ATRA-ATO arm
• Two therapy-related myeloid neoplasms in ATRA-CHT arm - NONE in ATRA-ATO arm

• UK AML Working Party Phase III RCT: ATRA + ATO vs. ATRA + chemotherapy (with/without GO)
• n = 235 patients (non-high-risk)
• 2-year OS: 93% ATRA-ATO vs. 89% ATRA-chemo
• Lower relapse rate, less toxicity with ATRA-ATO
• Confirmed ATRA-ATO superiority across different ATO dosing schedule

• Pediatric APL: confirmed ATRA + ATO effective and safer than ATRA-chemo in children
• Updated in AAML1331 (Kutny et al., JAMA Oncol 2022, PMID 34762093): ATO + ATRA equivalent to ATRA-chemo in pediatric APL

Era 4: Extending ATRA-ATO to High-Risk and Novel Approaches (2020-Present)

• Phase III RCT: ATRA + ATO + low-dose idarubicin (days 1,3) vs. ATRA-AIDA in high-risk APL (WBC >10,000/μL)
• n = 133 patients (68 ATRA-ATO, 65 ATRA-CHT)
• Primary endpoint: 2-year EFS: 88% ATRA-ATO vs. 71% ATRA-CHT (HR 0.4, P=0.02)
• Molecular relapse: 1.5% vs. 12.3% (P=0.014)
• Serious adverse events: 32% ATRA-ATO vs. 68% ATRA-CHT (P<0.01)
• Conclusion: ATRA + ATO + minimal idarubicin is now supported for high-risk APL - extends the ATRA-ATO paradigm to all risk groups

• Academic community partnership study addressing early mortality in APL
• Focused on real-world implementation of early ATRA initiation to reduce hemorrhagic death

• Systematic review and meta-analysis of 12 studies (GRADE framework)
• ATRA + ATO vs. ATRA + chemotherapy:
  • CR: RR 1.04 (95% CI 1.02-1.06)
  • DFS: RR 1.22 (95% CI 1.11-1.34)
  • EFS: RR 1.25 (95% CI 1.20-1.29)
  • OS: RR 1.07 (95% CI 1.03-1.12)
  • QTc prolongation higher with ATRA-ATO: RR 3.79 (P=0.05) - mandates cardiac monitoring
• Definitively confirms ATRA + ATO superiority across all outcomes

---

9. ORAL ATO - EMERGING DATA

• Phase III pediatric RCT (Huang et al., Blood Cancer J 2023, PMID 38052803): oral vs. IV ATO in children - equivalent efficacy and safety
• Significant pharmacoeconomic and logistic advantages (outpatient consolidation)
• Currently used widely in Asia; regulatory approval pending in Western countries

---

10. SPECIAL POPULATIONS

Pregnancy

• ATRA is teratogenic (Category X) in first trimester
• ATO is teratogenic and embryotoxic
• Manage with ATO alone in second/third trimester if possible, or deliver early
• Multidisciplinary approach mandatory

Elderly (>70 years)

• ATRA + ATO preferred (avoid anthracyclines)
• Full dose ATRA-ATO achievable with careful supportive care
• Dose reduction of ATO may be needed if QTc or renal issues

CNS Relapse

• CNS APL is rare (2-3%) but serious
• Managed with intrathecal cytarabine + MTX
• ATO penetrates CNS poorly - systemic therapy + IT chemotherapy needed

---

11. MONITORING AND TOXICITY MANAGEMENT

ATRA Toxicities

ATO Toxicities

---

12. PROGNOSIS

• WBC >10,000/μL at diagnosis
• CD56 expression (poor prognosis)
• FLT3-ITD mutation (associated with microgranular variant, high WBC)
• Secondary APL (therapy-related)
• Advanced age
• High LDH

---

13. SUMMARY OF CURRENT TREATMENT ALGORITHM (2026)

APL Suspected (bleeding + promyelocytes + morphology)
           ↓
IMMEDIATE ATRA 45 mg/m²/d + aggressive coagulopathy support
(Do NOT wait for FISH/PCR)
           ↓
FISH/PCR confirms PML-RARA
           ↓
       Risk stratify
       /           \
Standard-risk    High-risk (WBC >10,000)
(WBC ≤10,000)         ↓
     ↓         ATRA + ATO + idarubicin (days 1,3) [APOLLO]
ATRA + ATO     OR ATRA + AIDA (if ATO contraindicated)
(chemotherapy-        ↓
free; APL0406)  Cytoreduction with hydroxyurea + dexamethasone
     ↓          Watch for differentiation syndrome
Consolidation        ↓
4 cycles         Consolidation
ATRA + ATO       4 cycles ATRA + ATO
     ↓                ↓
PCR monitoring q3mo × 2 years
     ↓
PCR negative: CURE (no maintenance needed)
PCR positive: Salvage with ATO ± GO → Auto-HCT if molecular CR achieved

---

REFERENCES

1. Harrison's Principles of Internal Medicine 22E (2025), p.877 - Treatment of APL
2. Henry's Clinical Diagnosis and Management by Laboratory Methods - APL with PML-RARA
3. Goldman-Cecil Medicine - Table 168-3: Management of Newly Diagnosed APL
4. Lo-Coco F et al. NEJM 2013 - APL0406 initial results; ATRA+ATO vs ATRA+CHT, PMID 23841729
5. Platzbecker U et al. JCO 2017 - APL0406 final results at 50 months, PMID 27400939
6. Platzbecker U et al. JCO 2025 - APOLLO Trial: ATRA-ATO in high-risk APL, PMID 40825164
7. Ahmad H et al. BMC Cancer 2026 - GRADE meta-analysis ATRA+ATO vs ATRA+CHT, PMID 41906112
8. Mohty R et al. Transplant Cell Ther 2024 - HCT in relapsed APL meta-analysis, PMID 38554737
9. Yilmaz M et al. Blood Cancer J 2021 - Current APL treatment algorithms, PMID 34193815
10. Huang DP et al. Blood Cancer J 2023 - Oral vs IV ATO in pediatric APL, PMID 38052803
11. NCCN Guidelines AML v3.2026 (November 2025)

---

Complete APL Note - Summary Card

---

APL Management - Low Risk & High Risk

A Complete Expert Hematology Reference (2026)

---

STEP 0 - BEFORE ANYTHING ELSE: THE EMERGENCY RULE

Start ATRA the moment you suspect APL. Do not wait for FISH, PCR, or karyotype.

• ATRA 45 mg/m²/day orally in 2 divided doses - START NOW
• Platelet transfusion: maintain >50 × 10⁹/L (or >30 at minimum)
• Cryoprecipitate/FFP: maintain fibrinogen >150 mg/dL
• Check and correct K⁺ and Mg²⁺ (QTc risk with ATO)
• Baseline ECG (QTc before starting ATO)
• Baseline LFTs, creatinine
• Send FISH + RT-PCR for PML-RARA urgently
• No heparin. No LP until coagulopathy resolved.

---

RISK STRATIFICATION

• NCCN (2026) simplifies: Standard-risk = WBC ≤10,000/μL / High-risk = WBC >10,000/μL
• Low + intermediate = "non-high-risk" = treated identically (ATRA-ATO, no chemotherapy)

---

---

PART A: STANDARD-RISK APL (WBC ≤10,000/μL)

~70-75% of newly diagnosed APL patients

---

A1. INDUCTION - THE LO-COCO / APL0406 REGIMEN

• Bone marrow aspirate at hematologic recovery (platelets >100 × 10⁹/L, ANC >1 × 10⁹/L, typically day 28-42)
• Confirm morphologic CR (blasts <5%, no Auer rods)
• Molecular CR by PCR is NOT required after induction - aim for this after consolidation

---

A2. CONSOLIDATION - 4 CYCLES (No chemotherapy)

• ATO 0.15 mg/kg/day × 5 days/week for 4 consecutive weeks
• ATRA 45 mg/m²/day days 1-28 (or 2-week pulses per modified schedule)

• ATO 0.15 mg/kg/day × 5 days/week × 4 weeks
• ATRA 45 mg/m²/day × 2 weeks on / 2 weeks off within each cycle

• ATRA 45 mg/m²/day: Days 1-28
• ATO 0.15 mg/kg/day: Days 1-28

• ATRA 45 mg/m²/day: Days 1-7, 15-21, 29-35
• ATO 0.15 mg/kg/day: Days 1-5, 8-12, 15-19, 22-26, 29-33

---

A3. MAINTENANCE

• APL0406 trial: no maintenance in ATRA-ATO arm; 50-month CIR only 1.9%
• AML17 trial: no maintenance in ATRA-ATO arm; outcomes superior to ATRA-chemo with maintenance
• This is a definitive paradigm shift - spare patients 2 years of maintenance toxicity

Exception: If patient was treated with ATRA-chemotherapy (AIDA) due to ATO contraindication, give maintenance: ATRA 45 mg/m²/day × 15 days every 3 months + 6-mercaptopurine 50-90 mg/m²/day + methotrexate 5-15 mg/m² weekly for 2 years.

---

A4. MRD MONITORING AFTER CONSOLIDATION

PCR sensitivity: 10⁻⁴ to 10⁻⁵. A rising/persistent PCR after consolidation = treat before hematologic relapse.

---

A5. EXPECTED OUTCOMES - STANDARD RISK (ATRA-ATO)

---

---

PART B: HIGH-RISK APL (WBC >10,000/μL)

~25-30% of newly diagnosed APL patients - the clinical challenge

---

WHY HIGH-RISK IS DIFFERENT

• ATRA alone causes massive hyperleukocytosis (WBC can shoot to >50 × 10⁹/L within days) → fatal DS
• Higher rate of differentiation syndrome with ATRA
• More severe coagulopathy → higher early death rate (hemorrhagic)
• FLT3-ITD mutations more common (especially in microgranular M3v variant)
• Historically: 5-year RFS with ATRA-chemotherapy (AIDA) ~70-75% vs. ~90% for standard risk

• Hydroxyurea 0.5-1g every 6-8 hours to bring WBC down rapidly
• Dexamethasone 10 mg IV every 12 hours from Day 1 (DS prophylaxis when WBC >10,000)
• ATRA - begin simultaneously

---

B1. INDUCTION - HIGH-RISK APL

Option 1 (CURRENT PREFERRED): APOLLO Protocol - 2025

---

Option 2 (APML4 Protocol - Australian, still used):

---

Option 3 (Classic AIDA - if ATO contraindicated):

• Replace with AIDA
• Alternative: ATRA + daunorubicin + cytarabine (AML-like induction)
• Alternative in cardiac risk: ATRA + gemtuzumab ozogamicin (GO) ± ATO

---

Option 4 (NCCN 2026 - specific contraindication scenarios):

---

B2. END-OF-INDUCTION ASSESSMENT (HIGH-RISK)

• Bone marrow aspirate + biopsy at day 28 (or at count recovery)
• Confirm morphologic CR
• Consider LP (lumbar puncture) before consolidation - NCCN recommends this for high-risk patients (CNS APL rare but >2-3% in high-risk)
• PCR PML-RARA from marrow at end of induction

---

B3. CONSOLIDATION - HIGH-RISK APL

After APOLLO Protocol Induction:

After APML4 Induction:

• Consolidation 1: ATRA (days 1-15) + ATO 0.15 mg/kg/day (days 1-28)
• Consolidation 2: ATRA (days 1-15) + ATO (days 1-28)
• Then: Maintenance × 2 years (ATRA + 6-MP + MTX)

After AIDA Induction (chemotherapy-based):

---

B4. MAINTENANCE - HIGH-RISK (DEBATED)

• In the ATO era with APOLLO-type regimens: maintenance not routinely needed (molecular relapse <2% at 2 years)
• In AIDA-based regimens: 2 years maintenance is standard
• In APL15 trial and APML4: maintenance ATRA + 6-MP + MTX included for high-risk

Expert opinion (Chin & Tallman, Curr Opin Oncol 2025, PMID 41029961): The need for maintenance in high-risk patients treated with ATRA-ATO regimens remains under study. Current practice leans toward no maintenance after APOLLO-type regimens given very low relapse rates.

---

B5. EXPECTED OUTCOMES - HIGH-RISK APL

---

---

PART C: MANAGEMENT OF DIFFERENTIATION SYNDROME (DS)

• Fever (unexplained)
• Weight gain >5 kg
• Peripheral edema
• Pleural or pericardial effusion
• Pulmonary infiltrates / hypoxia (SpO₂ <90%)
• Renal failure (Cr rising)
• Hypotension

• Continue dexamethasone minimum 3 days, until complete resolution, then taper
• If rising WBC: add hydroxyurea ± cytarabine for cytoreduction
• Furosemide for fluid overload
• Resume ATRA/ATO at full dose once DS resolves (even severe cases can be restarted)

---

PART D: RELAPSED APL

D1. Confirm Relapse

• Molecular relapse: Rising PCR (2 consecutive positive results from PML-RARA negative baseline) - treat immediately, don't wait for morphologic relapse
• Hematologic relapse: Reappearance of leukemic promyelocytes in blood/marrow

---

D2. Salvage Therapy

If prior therapy was ATRA-chemotherapy (AIDA-based):

If prior therapy was ATRA-ATO (APL0406/APOLLO):

• ATRA + GO (gemtuzumab ozogamicin 9 mg/m² day 1, 15)
• ATRA + idarubicin-based chemotherapy + ATO
• Clinical trial enrollment strongly recommended

---

D3. Transplantation in Relapsed APL

• In modern ATRA-ATO era: 5-year OS with salvage = 71%
• SCT may NOT be needed after first relapse-CR2 in the ATO era (outcomes similar with vs. without SCT, P=0.848)
• Reserve allo-HCT for: PCR-positive at HCT, second or later relapse, inability to achieve molecular CR

Molecular or hematologic relapse
         ↓
Start ATO ± ATRA ± GO salvage
         ↓
Achieve molecular CR2 (PCR negative)
         ↓
If PCR negative: Auto-HCT (preferred)
If PCR positive: Allo-HCT (GVL needed)
If unable to achieve CR2: Clinical trial / Allo-HCT

---

LANDMARK AND LATEST TRIALS - COMPLETE TIMELINE

THE LANDMARK TRIALS EVERY HEMATOLOGIST MUST KNOW

---

1. ATRA Discovery - Shanghai 1988 (Huang et al., Blood 1988)

• What: First clinical use of pharmacologic ATRA in 24 APL patients
• Result: CR rate 96% - unheard of at the time
• Impact: Transformed APL from a rapidly fatal disease to a curable one overnight
• Evidence level: Historical cohort; no RCT needed - effect size was enormous

---

2. European APL Group - Fenaux et al., Blood 1993 (n=101)

• What: Randomized: ATRA → chemo vs. ATRA + chemo concurrent vs. chemo alone
• Result: 2-year DFS: concurrent ATRA-chemo 79% > ATRA then chemo 62% > chemo 50%
• Impact: Established concurrent ATRA + chemotherapy as standard of care

---

3. AIDA Trial - GIMEMA/PETHEMA 1997

• What: ATRA + idarubicin (no cytarabine) induction + anthracycline consolidation
• Result: CR ~95%; 5-year OS ~80%
• Impact: AIDA became the global chemotherapy-based standard for ~15 years
• Legacy: Still used when ATO is contraindicated

---

4. ATO in Relapsed APL - Shen et al., Blood 1997 (China)

• What: Arsenic trioxide monotherapy in relapsed/refractory APL
• Result: CR rate 85% with ATO alone
• Impact: Proved ATO was the single most active agent in APL; launched the ATO revolution

---

5. APL0406 Trial - Lo-Coco et al., NEJM 2013 ⭐ THE LANDMARK

• Design: Phase III RCT, n=156, non-high-risk APL (WBC ≤10 × 10⁹/L)
• Arms: ATRA + ATO (no chemo) vs. ATRA + idarubicin-chemo
• Results:

• Impact: Established ATRA + ATO as the new standard of care - eliminated chemotherapy from non-high-risk APL
• No maintenance needed in ATRA-ATO arm
• This single trial changed practice worldwide

---

6. APL0406 Final Analysis - Platzbecker et al., JCO 2017

• Median follow-up 40.6 months; 276 patients
• 50-month EFS: 97.3% vs. 80% (P<0.001)
• 50-month CIR: 1.9% vs. 13.9% (P=0.0013)
• 50-month OS: 99.2% vs. 92.6% (P=0.0073)
• 2 therapy-related myeloid neoplasms in chemo arm, zero in ATRA-ATO arm
• Impact: Confirmed superiority increases over time; definitively eliminated chemo from standard-risk APL

---

7. AML17 Trial - Burnett et al., Lancet Oncol 2015 (UK AML Working Party)

• Design: Phase III RCT, n=235 non-high-risk APL
• Arms: ATRA + ATO (alternative schedule: 0.3 mg/kg days 1-5, then 0.25 mg/kg twice weekly) vs. ATRA + IDA-based chemo ± GO
• Results: Lower relapse, better survival with ATRA-ATO
• 2-year OS: 93% ATRA-ATO vs. 89% ATRA-chemo
• Impact: Validated APL0406 findings with a different ATO dosing schedule; confirmed global applicability

---

8. APL15 Trial - Wang et al., Blood Cancer J 2022 ⭐ EXTENDS TO HIGH-RISK

• Design: Phase III non-inferiority RCT; Chinese multi-center; n=128 all-risk APL
• Arms: ATRA-ATO alone (+ hydroxyurea for WBC control) vs. ATRA-ATO + chemotherapy
• Key question: Can chemotherapy be eliminated even in high-risk APL?
• Results (high-risk subgroup):

• Impact: First RCT to show chemotherapy may be unnecessary even in high-risk APL, using ATO + ATRA + hydroxyurea alone

---

9. APOLLO Trial - Platzbecker, Adès, Montesinos et al., JCO 2025 ⭐ LATEST LANDMARK

• Design: Phase III RCT; European multicenter; specifically in high-risk APL (WBC >10,000/μL); n=133
• ATRA-ATO arm: ATRA + ATO + idarubicin days 1 & 3 only → then 4 cycles ATRA-ATO consolidation (no maintenance)
• ATRA-CHT arm: Classic AIDA induction → anthracycline consolidation × 3 cycles → 2 years maintenance
• Primary endpoint: 2-year EFS

• CONCLUSION: ATRA + ATO + minimal idarubicin is superior to ATRA-AIDA in high-risk APL
• No maintenance therapy needed in ATRA-ATO arm
• This trial NOW extends the ATRA-ATO paradigm to ALL risk groups

---

10. AAML1331 (Children's Oncology Group) - Kutny et al., JAMA Oncol 2022

• Pediatric APL: ATRA + ATO equivalent to ATRA + chemotherapy in children
• Confirmed ATRA-ATO can safely replace chemotherapy in pediatric standard-risk APL
• Impact: Extended chemotherapy-free treatment to children

---

11. Meta-Analysis - Ahmad et al., BMC Cancer 2026

• 12 studies, GRADE framework
• ATRA + ATO vs. ATRA + CHT across all risk groups:

• CONCLUSION: ATRA + ATO superior in all survival outcomes; close cardiac monitoring for QTc is mandatory

---

COMPLETE MANAGEMENT ALGORITHM (2026)

APL SUSPECTED → ATRA 45 mg/m²/d IMMEDIATELY + Coagulopathy support
                         ↓
               Confirm PML-RARA (FISH/PCR)
                         ↓
              RISK STRATIFY (WBC at diagnosis)
             /                              \
   WBC ≤10,000/μL                    WBC >10,000/μL
  (Standard Risk)                     (High Risk)
       ↓                                    ↓
  ATRA + ATO                    Add cytoreduction ASAP:
  (Lo-Coco protocol)            - Hydroxyurea 0.5-1g Q6-8h
       ↓                        - Dexamethasone 10 mg Q12h
  Monitor WBC;                  - Watch for DS aggressively
  add HU if rising                          ↓
       ↓               ┌──────────────────────────────────┐
       ↓               │  ATRA + ATO + IDA days 1&3       │
       ↓               │  (APOLLO - PREFERRED, 2025)      │
       ↓               │  OR                              │
       ↓               │  ATRA + ATO + IDA days 2,4,6,8   │
       ↓               │  (APML4)                         │
       ↓               │  OR (if ATO contraindicated)     │
       ↓               │  ATRA + AIDA                     │
       ↓               └──────────────────────────────────┘
       ↓                                    ↓
  INDUCTION RESPONSE ASSESSMENT (Day 28-42 BM biopsy)
                         ↓
                Morphologic CR achieved?
                         ↓ Yes
              ┌──────────────────────────┐
              │  4 cycles ATRA + ATO     │
              │  Consolidation           │
              │  (~28 weeks total)       │
              └──────────────────────────┘
                         ↓
              PCR PML-RARA after final cycle
                         ↓
               ┌──────────────────────┐
               │     PCR negative     │ → CURE. Surveillance PCR q3mo × 2yr
               └──────────────────────┘
               ┌──────────────────────┐
               │     PCR positive     │ → Molecular relapse protocol
               └──────────────────────┘
                         ↓
                   RELAPSE PATHWAY
                         ↓
          ATO ± ATRA ± GO salvage → CR2
                         ↓
          PCR negative: Auto-HCT (preferred)
          PCR positive: Allo-HCT
          Multiple relapse: Clinical trial

---

QUICK REFERENCE DRUG DOSING CARD

---

KEY CLINICAL PEARLS FROM WORLD-CLASS HEMATOLOGISTS

1. The biggest killer in APL is the first 48 hours - hemorrhagic death before ATRA is started. Every hour without ATRA is dangerous. Start empirically on clinical suspicion alone.
2. ATRA-ATO is now the paradigm for ALL risk groups (after APOLLO 2025) - chemotherapy's role is being reduced to 2 doses of idarubicin at most in high-risk, and zero doses in standard-risk.
3. Differentiation syndrome is a clinical diagnosis - don't wait for all criteria. Start dexamethasone early. Mortality drops from 10% to near zero with early treatment.
4. PCR-negativity after consolidation is the cure criterion - not just morphologic CR. A patient who is morphologically in CR but PCR-positive after final consolidation will relapse.
5. Oral ATO (10 mg/day) is bioequivalent to IV - game-changing for resource-limited settings and outpatient care. APL can become an outpatient-treated disease.
6. In the ATO era, SCT for relapsed APL may be optional - MDACC data (Sasaki 2024) show similar outcomes with or without transplant after first relapse if molecular CR is achieved with ATRA-ATO salvage.
7. FLT3-ITD mutation in APL - present in ~30-40% of high-risk/M3v APL. Not yet a treatment-changing finding (does not affect ATRA-ATO response), but flags higher-risk biology.
8. PLZF-RARA is ATRA-resistant - if the patient is not responding morphologically to ATRA, question the diagnosis and check for variant translocation.

---

• Harrison's Principles of Internal Medicine 22E (2025), p.877
• Goldman-Cecil Medicine, Table 168-3
• Lo-Coco F et al., NEJM 2013 - APL0406 initial (PMID 23841729)
• Platzbecker U et al., JCO 2017 - APL0406 final (PMID 27400939)
• Platzbecker U et al., JCO 2025 - APOLLO Trial (PMID 40825164)
• Wang HY et al., Blood Cancer J 2022 - APL15 Trial (PMID 36404343)
• Ahmad H et al., BMC Cancer 2026 - 2026 meta-analysis (PMID 41906112)
• Mohty R et al., Transplant Cell Ther 2024 - HCT in relapsed APL (PMID 38554737)
• Sasaki K et al., Clin Lymphoma Myeloma Leuk 2024 - Relapsed APL outcomes (PMID 38431521)
• Chin KK & Tallman MS, Curr Opin Oncol 2025 - Curative strategies high-risk APL (PMID 41029961)
• Alberta Health Services APL Guideline, revised October 2025
• NCCN AML Guidelines v3.2026

---

KIMURA DISEASE - A Complete Clinical Note

---

1. DEFINITION

1. Painless subcutaneous nodules predominantly in the head and neck region
2. Peripheral blood eosinophilia
3. Markedly elevated serum IgE

• Fitzpatrick's Dermatology, p.697-699
• Comprehensive Clinical Nephrology, 7th Edition, p.416
• K.J. Lee's Essential Otolaryngology

---

2. HISTORICAL BACKGROUND

---

3. EPIDEMIOLOGY

Notable: A retrospective series from the US Armed Forces Institute of Pathology found 7 whites, 6 African Americans, 6 Asians among 21 cases - illustrating that Kimura disease must be considered in any racial group.

---

4. ETIOLOGY AND PATHOGENESIS

4.1 Th2-Driven Immune Dysregulation (Most Accepted Theory)

• KD is driven by aberrant Th2 immune responses
• Th2 cytokines (IL-4, IL-5, IL-13) promote:
  • IgE class switching → markedly elevated serum IgE
  • Eosinophil recruitment and survival (IL-5) → tissue eosinophilia
  • Mast cell activation → pruritus, allergic features
• The pathogenesis parallels atopic disease, explaining the frequent co-occurrence with asthma and allergic rhinitis

4.2 Proposed Triggers

• Allergic reaction/hypersensitivity - supported by elevated IgE and eosinophilia
• Parasitic infection - geographic distribution, eosinophilia; however, no consistent pathogen identified
• Autoimmune mechanism - salivary gland involvement, lymphoid hyperplasia, renal immune complex deposition
• Viral trigger - speculated but unproven

4.3 Molecular Pathways (Recent Evidence)

• PDGF-α and c-kit expression found in KD tissue → rationale for tyrosine kinase inhibitors (imatinib), though not yet used clinically
• IgG4-related disease overlap - 11.3% of KD patients have co-existing IgG4-RD (Zhu et al. 2025), suggesting overlapping fibroinflammatory mechanisms
• Type 2 inflammation pathway (IL-4/IL-5/IL-13/IgE axis) - supported by responses to biologic agents targeting these pathways

---

5. PATHOLOGY / HISTOPATHOLOGY

5.1 Gross Pathology

• Firm, poorly circumscribed nodules in subcutaneous tissue
• Often involves adjacent lymph nodes and salivary glands
• No capsule; infiltrative margins

5.2 Microscopic Features (Diagnostic)

5.3 Immunohistochemistry

---

6. CLINICAL FEATURES

6.1 Primary Presentation

• Painless subcutaneous nodules - most common presenting feature
• Location: head and neck (83%) - most commonly preauricular, retroauricular, submandibular, posterior neck regions
• Nodules: slow-growing, diffuse, poorly defined; median size ~3.0 cm
• Bilateral in 66% of cases (Zhu et al. 2025)
• Pruritus overlying nodules - present in ~52.8%; increases with age

6.2 Site-Specific Features

6.3 Systemic and Associated Features

---

7. LABORATORY INVESTIGATIONS

7.1 Blood Tests

7.2 Imaging

7.3 Tissue Biopsy (Mandatory for Diagnosis)

• Incisional biopsy is recommended (over needle biopsy for adequate tissue)
• Biopsy of the subcutaneous nodule and/or lymph node
• Light microscopy + immunohistochemistry required
• Diagnosis is histopathologic - there are no pathognomonic serologic tests

---

8. DIAGNOSIS

Diagnostic Criteria (No formal validated criteria, but commonly used features):

1. Painless subcutaneous nodule(s) in head and neck
2. Peripheral eosinophilia
3. Elevated serum IgE

---

9. DIFFERENTIAL DIAGNOSIS

9.1 Most Important: Kimura Disease vs. ALHE

---

9.2 Broader Differential Diagnosis

---

10. RENAL INVOLVEMENT IN KIMURA DISEASE

10.1 Glomerular Patterns

10.2 Clinical Presentation of Renal Disease

• Nephrotic syndrome (proteinuria >3.5g/day, hypoalbuminemia, edema, hyperlipidemia)
• Microscopic hematuria occasionally
• Renal function usually preserved initially but can decline

10.3 Pathogenesis of Renal Involvement

• Immune complex deposition (IgE-containing complexes) in glomeruli
• Eosinophil-mediated glomerular injury
• Th2 cytokine-driven mesangial proliferation

10.4 Investigation for Renal Involvement (All KD Patients)

• Urinalysis + microscopy (protein, casts)
• 24-hour urine protein (or protein/creatinine ratio)
• BUN, creatinine, albumin
• Renal ultrasound if proteinuria
• Renal biopsy if nephrotic range proteinuria

10.5 Management of Renal Disease

• Influences treatment choice for KD (see management section)
• Steroid therapy most effective when nephrotic syndrome is present
• Steroid-sparing agents for relapsing/steroid-dependent nephrotic syndrome

---

11. MANAGEMENT

---

11.1 Treatment Ladder

Asymptomatic / mild disease
         ↓
Observation (watchful waiting)
         ↓
Single/limited nodules without renal disease
         ↓
Surgery (first-line when feasible)
         ↓
Multiple/diffuse nodules / recurrence / renal involvement
         ↓
Systemic corticosteroids
         ↓
Refractory / steroid-dependent / recurrent
         ↓
Steroid-sparing immunosuppressants
         ↓
Refractory / severe / recurrent with atopic features
         ↓
Biologic therapy (dupilumab / mepolizumab / omalizumab)
OR Radiotherapy (for localized/unresectable disease)

---

11.2 Observation (Watchful Waiting)

• Appropriate for asymptomatic, small, stable lesions with no renal involvement
• Regular monitoring: blood count, IgE, urinalysis every 3-6 months
• No treatment needed if no progression

---

11.3 Surgery

• Modality of choice for localized, resectable disease
• Achieves histologic diagnosis + therapeutic excision simultaneously
• Most common initial treatment (62.3% in Zhu et al. 2025 series)
• Limitation: high recurrence rate - lesions recur in draining lymphatics and adjacent tissues
• Not curative for multifocal or diffuse disease
• Facial disfigurement is a concern with large cervicofacial lesions
• Photodynamic therapy has been used for postsurgical facial disfigurement (Abbas et al., case report)

---

11.4 Systemic Corticosteroids

Comprehensive Clinical Nephrology: "Steroid therapy is successful in most cases, although relapse upon tapering is common."

---

11.5 Steroid-Sparing / Immunosuppressive Agents

---

11.6 Radiotherapy

---

11.7 Biologic Therapies - THE EMERGING FRONTIER (2022-2025)

A. Dupilumab (IL-4Rα antagonist - blocks IL-4 and IL-13 signaling)

• Rationale: IL-4/IL-13 drive IgE class switching and Th2 responses in KD
• Multiple case reports (2022-2024) showing efficacy:
  • Shang et al. (2023): Significant clinical response
  • Battesti et al., Clin Exp Dermatol (2024): 2 dupilumab-responsive cases
  • Luo et al., Int Immunopharmacol (2024): Dupilumab effective with literature review
  • Yang et al., Front Immunol (2022): Response independent of IgE level - suggests mechanism beyond just IgE suppression
  • Liu et al., QJM (2024): Efficacy and safety of dupilumab confirmed
• Works even in IgE-independent fashion, targeting the upstream Th2 pathway
• Growing evidence base - becoming the most studied biologic for KD

B. Mepolizumab (Anti-IL-5 - depletes eosinophils)

• Rationale: IL-5 is the principal eosinophil survival factor
• Zhu et al. (J Inflamm Res, 2025, PMID 41070115) - 3 mepolizumab-responsive cases:
  • Lymph node shrinkage
  • Pruritus reduction (VAS 8 → 2)
  • Eosinophilia improved over time
  • Corticosteroids successfully tapered off within 6 months
  • Dose: 200 mg every 4 weeks (also 100 mg every 4 weeks used)
• Particularly useful when asthma coexists (KD + asthma = both benefit from IL-5 blockade)
• Serum IgE remained elevated despite clinical response (IgE not a surrogate marker of mepolizumab response)

C. Omalizumab (Anti-IgE)

• Rationale: Directly neutralizes free IgE; prevents IgE-mediated mast cell/basophil activation
• Ao et al. (J Dermatol, 2024, PMID 37950550) - 2 refractory cases responded to low-dose steroid + omalizumab; reviewed 13 biologic-treated KD cases
• Reduces IgE-mediated inflammation
• Less consistent response than dupilumab; IgE levels may remain elevated

D. Benralizumab (Anti-IL-5Rα)

• Rapidly depletes eosinophils by ADCC
• Limited case reports; promising based on mechanism

E. Rituximab (Anti-CD20 B-cell depletion)

• Reviewed in Ao et al. 2024 series
• Used in cases with B-cell-driven lymphoid hyperplasia component
• Less evidence than dupilumab/mepolizumab

Th2 immune dysregulation in KD:
                    ↓
         IL-4 / IL-13 pathway
         → IgE production
         → Mast cell activation        ← Omalizumab blocks IgE
         → B cell class switching      ← Dupilumab blocks IL-4Rα
                    +
         IL-5 pathway
         → Eosinophil survival/migration ← Mepolizumab/Benralizumab block IL-5

---

11.8 Antihistamines

• Cetirizine and other antihistamines used for pruritus management
• Not disease-modifying - used adjunctively
• Effective symptomatic relief given the mast cell/IgE-driven itch

---

11.9 Cryotherapy

• Used occasionally for small superficial lesions
• Limited durability; rarely used as primary therapy

---

12. MANAGEMENT BY CLINICAL SCENARIO

---

13. PROGNOSIS

Factors associated with recurrence:

• Large lesion size
• Bilateral disease
• Involvement of salivary glands
• Inadequate initial treatment
• Delay in diagnosis (median 24 months in current series)

---

14. MONITORING PLAN

---

15. SUMMARY TABLE

---

REFERENCES

1. Fitzpatrick's Dermatology, 9th Edition, Chapter 40 - Kimura Disease, p.697-699
2. Comprehensive Clinical Nephrology, 7th Edition - Kimura Disease, p.416
3. Cummings Otolaryngology Head and Neck Surgery - Kimura Disease, Chapter 17
4. K.J. Lee's Essential Otolaryngology - Kimura Disease, p.49
5. Lagerstrom IT et al., Head Neck Pathol, 2025 - Comprehensive systematic review of KD (PMID 40549072)
6. Zhu W et al., J Inflamm Res, 2025 - 53-case retrospective analysis + mepolizumab cases (PMID 41070115)
7. Ao S et al., J Dermatol, 2024 - Anti-IgE (omalizumab) + biologic review in KD (PMID 37950550)
8. Yang B et al., Front Immunol, 2022 - Dupilumab in KD independent of IgE (PMID 36591252)
9. Zhang G et al., BMC Surg, 2020 - Clinical analysis of 24 KD cases from China (PMID 31898499)
10. Alberta Health Services / Medscape - Kimura disease treatment protocols (2024-2025)

---

Refractory ITP - Complete Expert Hematology Note (2026)

---

1. DEFINITION OF REFRACTORY ITP

30-40% of ITP patients develop relapsed/refractory disease after first-line treatment (Washington Manual of Medical Therapeutics). Refractory ITP represents a significant unmet need.

---

2. PATHOGENESIS (Why ITP Becomes Refractory)

                    ┌─────────────────────────────┐
                    │    Immune Dysregulation      │
                    └─────────────────────────────┘
                                   │
          ┌────────────────────────┼────────────────────────┐
          ▼                        ▼                        ▼
   B-cell Activation        T-cell Dysregulation    Innate Immunity
   → Autoantibodies         → Loss of Treg           → Macrophage FcγR
   (anti-GPIIb/IIIa,        → Th1 > Th2 shift         platelet destruction
    anti-GPIb/IX)                                     → Direct NK killing
          │                        │                        │
          ▼                        ▼                        ▼
   IgG-coated platelets    Impaired tolerance        Spleen/liver clearance
   → Splenic destruction   → Cytotoxic T cells       → Reduced megakaryopoiesis
          │                  destroy platelets
          ▼
   FcRn recycling keeps autoantibody levels high

• Expanded autoantibody-secreting long-lived plasma cells (not cleared by rituximab)
• Persistent T-cell–mediated platelet destruction even without antibodies
• Complement activation contributing to platelet lysis
• Impaired megakaryopoiesis (insufficient thrombopoiesis even with normal TPO)

---

3. TREATMENT OVERVIEW - THE HIERARCHY

First-line (not refractory - background)

• Corticosteroids (dexamethasone 40 mg/day × 4 days, or prednisone 1 mg/kg/day)
• IVIG 1 g/kg × 1-2 doses (for acute bleeding / rapid rise needed)
• Anti-D immunoglobulin (Rh-positive, non-splenectomized only)

Second-line (standard - when steroids fail/relapse)

• TPO receptor agonists (TPO-RAs) - romiplostim, eltrombopag, avatrombopag
• Rituximab - anti-CD20
• Splenectomy

Third-line / Refractory

• Fostamatinib (SYK inhibitor - approved)
• Rilzabrutinib (BTK inhibitor - Phase 3 positive, under regulatory review 2025)
• Efgartigimod (FcRn inhibitor - Phase 3 positive, approved in some indications)
• Ianalumab + eltrombopag (Phase 3 positive, NEJM 2026)
• Immunosuppressives (cyclosporine, mycophenolate, azathioprine, danazol)
• Splenectomy (if not yet done)
• Combination therapies

---

4. STANDARD SECOND-LINE THERAPIES (Backbone before "refractory" label)

4.1 TPO Receptor Agonists (TPO-RAs)

• Start 5-7 days to first response; weekly adjustments by 1 μg/kg (romiplostim)
• 90%+ achieve platelet response in the short term
• ~30% achieve sustained treatment-free response after extended use (durable disease modification seen)
• Adverse effects: thromboembolic events (0-9%), bone marrow reticulin (monitor), rebound thrombocytopenia on stopping
• Eltrombopag: food interaction (take fasting 2h before/4h after dairy, antacids, calcium)
• ASH 2025 draft guidelines: TPO-RA is the preferred second-line agent (strong recommendation, moderate certainty)

4.2 Rituximab

4.3 Splenectomy

---

5. REFRACTORY ITP TREATMENT - APPROVED AGENTS

5.1 Fostamatinib (Tavalisse) - FDA Approved 2018

• SYK is critical in FcγR-mediated macrophage phagocytosis of IgG-opsonized platelets
• Blocking SYK reduces platelet destruction without immunosuppression

• Stable response by week 24: OR 0.80 (95% CI 0.72-0.88) - superior to placebo
• Platelet ≥50,000 at week 12: OR 0.80; at week 24: OR 0.82
• Effective even in patients with platelet baseline <15,000/μL
• NNT = 10 (clinically meaningful)

---

6. REFRACTORY ITP - LATEST TRIALS AND EMERGING AGENTS (2022-2026)

---

6.1 RILZABRUTINIB (BTK Inhibitor) - THE BREAKTHROUGH AGENT 2025

• BTK is expressed in B cells AND macrophages
• Dual mechanism:
  1. Reduces autoantibody production (B-cell receptor signaling blockade)
  2. Reduces FcγR-mediated platelet phagocytosis by macrophages
• Reversible covalent binding = avoids off-target cardiac/bleeding effects of irreversible BTK inhibitors (ibrutinib)

Phase 1/2 Trial (Kuter et al., NEJM 2022, PMID 35417637)

• n=60 heavily pre-treated adults (median 4 prior therapies, median platelet 15 × 10⁹/L, median disease 6.3 years)
• Dose: 400 mg BID established as optimal
• Platelet response (≥50 × 10³/μL × 2 consecutive): 40%
• Median time to first platelet ≥50 × 10³/μL: 11.5 days (very rapid)
• All treatment-related adverse events grade 1-2; no grade 2+ bleeding or thrombosis
• Conclusion: Active, safe, rapid onset - established 400 mg BID for Phase 3

LUNA 3 Trial - Phase 3 RCT (Kuter et al., Blood 2025, PMID 40090011) ⭐ LANDMARK

• Design: Randomized, double-blind, placebo-controlled, 24-week, multicenter Phase 3
• n=202 adults with persistent/chronic ITP
• Population: Median age 47, 63% female, 7.7-year median ITP duration, 28% prior splenectomy, median 4 prior therapies
• Rilzabrutinib: 400 mg BID (n=133) vs. Placebo (n=69)

• Adverse events: predominantly grade 1-2; one serious grade 3 peripheral embolism (multiple risk factors); one death from unrelated pneumonia
• No significant cardiac arrhythmias, hepatic toxicity, or increased major bleeding (unlike irreversible BTK inhibitors)
• ASH 2024 presentation; full publication Blood June 2025
• FDA target action date: August 29, 2025 - regulatory review ongoing
• Conclusion: First BTK inhibitor to show positive Phase 3 results in ITP; first-in-class oral agent with dual mechanism

---

6.2 EFGARTIGIMOD (FcRn Inhibitor) - ADVANCE IV (Lancet 2023)

• FcRn normally recycles IgG antibodies to prevent their degradation
• Efgartigimod blocks FcRn → accelerates IgG degradation → reduces all IgG subclasses including anti-platelet autoantibodies

ADVANCE IV Trial (Broome et al., Lancet 2023, PMID 37778358)

• Phase 3, multicenter, double-blind, RCT; n=131
• Population: Chronic/persistent ITP; mean 10.6 years since diagnosis; 67% had ≥3 prior ITP treatments; heavily pretreated
• Dose: Efgartigimod 10 mg/kg IV → flexible weekly/every 2 weeks based on platelet count
• Primary endpoint (chronic population): Sustained platelet ≥50 × 10⁹/L for ≥4 of last 6 weeks

• Well tolerated; most AEs grade 1-2; headache ~16%, no increased serious infections
• SC formulation (efgartigimod PH20 = subcutaneous) also under study; more convenient
• Conclusion: Positive Phase 3; modest but significant response in a very refractory population; IgG-reduction mechanism is broad
• Note: Response rate lower than other agents because population was heavily pretreated (mean 10+ years disease)

---

6.3 IANALUMAB + ELTROMBOPAG - VAYHIT2 (NEJM April 2026) ⭐ NEWEST LANDMARK

• BAFF-R (B-cell activating factor receptor) is essential for B-cell survival and activation
• Ianalumab depletes B cells via:
  1. Antibody-dependent cellular cytotoxicity (ADCC)
  2. BAFF-R signaling blockade → B-cell apoptosis
• Finite course (only 4 monthly infusions) → potential for sustained disease modification after treatment completion

VAYHIT2 Trial (Cuker et al., NEJM 2026, PMID 41363800) - Published April 2026

• Phase 3, multicenter, double-blind, RCT, n=152
• Population: Adults with primary ITP who failed/relapsed after first-line corticosteroids; platelet <30 × 10⁹/L at entry
• Design: 1:1:1 randomization to:
  • Ianalumab 9 mg/kg monthly × 4 months + eltrombopag
  • Ianalumab 3 mg/kg monthly × 4 months + eltrombopag
  • Placebo monthly × 4 months + eltrombopag
• Eltrombopag given in all arms, then tapered and stopped by week 24

• Published in NEJM April 2026 - the most recent landmark ITP trial
• Key innovation: Short-course biologic (4 doses only) that may modify disease course; allows eltrombopag tapering and stopping
• Higher SAE rate with 9 mg/kg; 3 mg/kg may be preferred safety profile
• ASH 2025 LBA-2 presentation - featured as late-breaking abstract
• Conclusion: Ianalumab + eltrombopag offers a time-limited treatment that modifies disease course in second-line ITP, extending time to treatment failure significantly beyond a TPO-RA alone

---

6.4 RECOMBINANT HUMAN TPO (rhTPO) - Chinese RCT Data

Liu et al., Platelets 2023 (PMID 36597010)

• Multicenter RCT of different dosing schedules of rhTPO in relapsed/refractory ITP
• rhTPO 300 IU/kg/day × 14 days vs. alternative schedules
• Significant platelet response; shorter time to response with intensive dosing
• Used widely in China; not yet approved in Western countries

---

6.5 AGENTS IN ONGOING TRIALS

---

7. CONVENTIONAL IMMUNOSUPPRESSIVES FOR REFRACTORY ITP

---

8. COMBINATION THERAPY FOR REFRACTORY ITP

---

9. SPLENIC EMBOLIZATION (Alternative to Splenectomy)

• Partial splenic embolization as alternative/adjunct to splenectomy
• Reduces splenic platelet destruction without surgical risk
• Short-term response comparable to surgery in non-surgical candidates
• Complication rate: Fever, pain (common); infarction, abscess (uncommon)
• Role in refractory ITP still being defined

---

10. EMERGENCY MANAGEMENT OF REFRACTORY ITP BLEEDING

---

11. ASH 2025 UPDATED DRAFT GUIDELINES - KEY RECOMMENDATIONS

---

12. COMPLETE MANAGEMENT ALGORITHM (2026)

ITP Diagnosed
     ↓
TREATMENT INDICATED?
(Platelets <30 × 10⁹/L OR bleeding symptoms)
     ↓ Yes
FIRST LINE:
Dexamethasone 40 mg × 4 days ± IVIG
     ↓
Response?
  ├── Yes → Monitor; manage relapse
  └── No / Relapse → SECOND LINE
          ↓
     SECOND LINE:
     ┌──────────────────────────────────┐
     │ TPO-RA (preferred, ASH 2025)     │ ← romiplostim / eltrombopag / avatrombopag
     │ OR Rituximab (if want finite Rx) │ ← 375 mg/m² × 4 wks
     │ OR Splenectomy (if >12 months)   │ ← 66-72% durable response
     └──────────────────────────────────┘
          ↓
     Response? 
     ├── Yes → Maintain; attempt TPO-RA tapering
     └── No / Relapse → REFRACTORY PROTOCOL
               ↓
     REFRACTORY ITP (≥2 lines failed):
     ┌─────────────────────────────────────────────────────┐
     │ APPROVED:                                           │
     │ Fostamatinib 100→150 mg BID (SYK inhibitor)        │
     │ Rilzabrutinib 400 mg BID* (BTK inhibitor)          │
     │ Efgartigimod IV (FcRn inhibitor)                   │
     │                                                     │
     │ COMBINATION (NEJM 2026):                           │
     │ Ianalumab + eltrombopag (if 2nd-line relapse)      │
     │                                                     │
     │ CONVENTIONAL:                                       │
     │ Cyclosporine / MMF / Azathioprine / Danazol/Dapsone│
     │                                                     │
     │ SPLENECTOMY (if not yet done)                      │
     └─────────────────────────────────────────────────────┘
               ↓
     Still refractory?
     → Clinical trial (anti-CD38, complement inhibitors)
     → Combination therapy
     → Palliative/supportive (target platelets >20-30 for safety)

---

13. LANDMARK AND LATEST TRIALS - TIMELINE

---

14. QUICK COMPARISON TABLE - REFRACTORY ITP AGENTS

---

REFERENCES

1. Washington Manual of Medical Therapeutics - ITP Treatment, p.758
2. Sabiston Textbook of Surgery - ITP, second-line therapy, p.1473
3. Kuter DJ et al., NEJM 2022 - Rilzabrutinib Phase 1/2 (PMID 35417637)
4. Kuter DJ et al., Blood 2025 - LUNA3 Phase 3 rilzabrutinib (PMID 40090011)
5. Cuker A et al., NEJM 2026 - VAYHIT2 ianalumab + eltrombopag (PMID 41363800)
6. Broome CM et al., Lancet 2023 - ADVANCE IV efgartigimod (PMID 37778358)
7. Tungjitviboonkun S et al., Ann Hematol 2024 - Fostamatinib meta-analysis (PMID 38856778)
8. Al-Samkari H & Neufeld EJ, Br J Haematol 2023 - Novel therapeutics for refractory ITP (PMID 37735554)
9. Egbaria A et al., Br J Haematol 2024 - Splenic embolization meta-analysis (PMID 38544461)
10. Ghanima W et al., Hematology ASH Educ Program 2024 - ITP management algorithm (PMID 39643995)
11. ASH 2025 Updated Draft Guidelines on Adult ITP (public comment December 2025)
12. Sanofi Press Release ASH 2024 - LUNA3 Phase 3 primary results; rilzabrutinib FDA target action date August 29, 2025

---

Multiple Myeloma - Complete Treatment Note

All Trials: Landmark Through June 2026

---

1. TREATMENT FRAMEWORK OVERVIEW

1. Transplant eligibility (transplant-eligible / transplant-ineligible)
2. Disease stage (newly diagnosed / relapsed-refractory)
3. Risk status (standard vs. high-risk cytogenetics)

Drug Classes in Use

---

2. SMOLDERING MULTIPLE MYELOMA (SMM)

Definition

High-risk SMM Definition (IMWG 2020)

Treatment of High-Risk SMM

• Phase 3 RCT; n=390; median follow-up 65.2 months
• Subcutaneous daratumumab monotherapy vs. active monitoring for 36 months (39 cycles)
• Primary endpoint: PFS (time to active myeloma or death)

• Most common grade 3-4 AE: hypertension 5.7% vs 4.6%
• Impact: FDA approved SC daratumumab for high-risk SMM in November 2025 - first ever approved treatment for SMM
• Practice shift: Young patients with high-risk SMM can now be treated to delay/prevent active myeloma

---

3. NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - TRANSPLANT ELIGIBLE

3.1 INDUCTION (Pre-ASCT)

GRIFFIN Trial (Blood 2020) - Transplant Eligible, US

• Phase 2 RCT: D-VRd vs. VRd in transplant-eligible NDMM
• stringCR rate: 62% D-VRd vs. 27% VRd
• Established quadruplet as superior; paved way for Phase 3

CASSIOPEIA Trial (Moreau et al., Lancet 2019) - Transplant Eligible, European

• Phase 3 RCT: Dara-VTd (daratumumab + bortezomib + thalidomide + dexamethasone) vs. VTd
• sCR rate: 29% Dara-VTd vs. 20% VTd (P<0.0001)
• Established daratumumab quadruplet benefit in Europe

PERSEUS Trial (Sonneveld et al., NEJM 2024, PMID 38084760) ⭐ LANDMARK

• Phase 3 RCT; n=709 transplant-eligible NDMM
• Dara-VRd (induction + consolidation + lenalidomide maintenance) vs. VRd + lenalidomide maintenance
• Daratumumab SC throughout

• Impact: D-VRd is NOW the preferred induction for transplant-eligible NDMM (NCCN 2024-2026)

GMMG-HD7 Trial (Mai et al., JCO 2025, PMID 39652594)

• Transplant-eligible NDMM: Isatuximab-VRd vs. VRd induction
• MRD negativity significantly improved with Isa-VRd
• Supports isatuximab quadruplet as European alternative

3.2 AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)

• High-dose melphalan (MEL200, 200 mg/m²) + ASCT remains the consolidation standard for eligible patients
• ASCT continues to improve depth of response and PFS even in the CD38 antibody era
• Patient selection: Age typically ≤70 years, adequate organ function, ECOG 0-2

• IFM 2009 (Attal et al., NEJM 2017): ASCT superior to no ASCT even with VRd - ASCT still extends PFS
• MIDAS Trial (Perrot et al., NEJM July 2025, PMID 40459097): MRD-guided consolidation - MRD-negative patients can skip ASCT without loss of deep remission (see below)

MIDAS Trial - MRD-Guided Therapy (Perrot et al., NEJM 2025) ⭐ PARADIGM-SHIFTING

• Phase 3; n=718 transplant-eligible NDMM; induction = Isa-KRd
• After induction, stratified by MRD status:

• ASCT group: ASCT + 2 cycles Isa-KRd consolidation
• Isa-KRd group: 6 cycles Isa-KRd (no ASCT)
• MRD-negative at 10⁻⁶ pre-maintenance: 86% (ASCT) vs. 84% (Isa-KRd) — NOT significantly different (P=0.64)

• Tandem ASCT vs. single ASCT + Isa-KRd
• MRD-negative at 10⁻⁶ pre-maintenance: 32% vs. 40% — NOT significantly different (P=0.31)
• Conclusion: MRD-negative patients after modern quadruplet induction can safely avoid ASCT without sacrificing remission depth — the first evidence that ASCT may become optional in MRD-guided strategies
• Impact: Will fundamentally change how we approach ASCT selection in the future

3.3 POST-ASCT MAINTENANCE

• Lenalidomide 10 mg/day (days 1-21 of 28-day cycle) until progression
• Reduces relapse risk by ~50%; OS benefit demonstrated

• Bortezomib maintenance (for high-risk cytogenetics: del17p, t(4;14)): 1.3 mg/m² SC every 2 weeks
• Daratumumab maintenance post-ASCT: Under study (AURIGA trial - showing superior MRD negativity rates with Dara maintenance)
• Isatuximab maintenance: Being investigated

---

4. NEWLY DIAGNOSED MULTIPLE MYELOMA - TRANSPLANT INELIGIBLE

4.1 GOLD STANDARD: Daratumumab + Lenalidomide + Dexamethasone (D-Rd)

MAIA Trial (Facon et al., Lancet 2019 + NEJM 2021 + Leukemia 2025)

• Phase 3 RCT; n=737; transplant-ineligible NDMM
• D-Rd vs. Rd until progression

• Impact: D-Rd is the standard of care for transplant-ineligible NDMM; OS benefit confirmed at 5+ years

4.2 QUADRUPLET FOR TRANSPLANT-INELIGIBLE: D-VRd

CEPHEUS Trial (Usmani et al., Nat Med 2025, PMID 39910273)

• Phase 3 RCT; n=395; transplant-ineligible or transplant-deferred NDMM
• D-VRd (8 cycles) → D-Rd until progression vs. VRd (8 cycles) → Rd until progression
• Primary endpoint: MRD-negativity rate at 10⁻⁵

• Conclusion: D-VRd is a new standard of care for transplant-ineligible/deferred NDMM

4.3 ISATUXIMAB-BASED QUADRUPLETS

IMROZ Trial (Facon et al., NEJM Oct 2024, PMID 38832972)

• Phase 3 RCT; n=446; transplant-ineligible NDMM (ages 18-80)
• Isa-VRd vs. VRd alone (3:2 randomization)
• Median follow-up 59.7 months (longest follow-up in any NDMM quadruplet trial)

• Impact: Longest-follow-up quadruplet trial; confirmed sustained PFS benefit at 5 years

BENEFIT Trial (Leleu et al., Nat Med 2024, PMID 38830994)

• Phase 3 RCT; n=270; transplant-ineligible NDMM (ages 65-79)
• Isa-VRd vs. Isa-Rd (adding bortezomib to isatuximab-Rd backbone)
• Primary endpoint: 18-month MRD negativity at 10⁻⁵

• Conclusion: Adding bortezomib to isatuximab-Rd (making Isa-VRd) significantly improves MRD outcomes even over Isa-Rd

---

5. RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

5.1 FIRST RELAPSE (1-3 prior lines)

Standard Regimens at First Relapse

5.2 CAR-T CELL THERAPY MOVING EARLIER

CARTITUDE-4 (San-Miguel et al., NEJM 2023, PMID 37272512) ⭐ LANDMARK

• Phase 3 RCT; n=419; lenalidomide-refractory NDMM (1-3 prior therapies)
• Cilta-cel (single infusion) vs. standard care (physician's choice: DPd or DVd)

• Impact: Cilta-cel FDA approved as early as second-line therapy in lenalidomide-refractory disease (April 2024)
• Update data (30-month PFS rate for those alive + progression-free at 1 year = 93%) - extraordinary durability

KarMMa-3 (Rodriguez-Otero et al., NEJM 2023, PMID 36762851)

• Phase 3 RCT; n=386; triple-class exposed RRMM (2-4 prior regimens, refractory to last line)
• Ide-cel (150-450 × 10⁶ CAR+ T cells) vs. 5 standard regimens
• 66% triple-class refractory; 95% daratumumab-refractory

• Impact: Ide-cel FDA approved in triple-class exposed RRMM after 2-4 prior lines

5.3 BISPECIFIC ANTIBODIES

MajesTEC-3 Trial (Costa et al., NEJM 2026, PMID 41363801) ⭐ NEWEST LANDMARK - NEJM Feb 2026

• Phase 3 RCT; n=587; RRMM with 1-3 prior lines
• Teclistamab (anti-BCMA × anti-CD3) + Daratumumab vs. DPd or DVd (standard)

• The most remarkable PFS data seen in early relapsed myeloma: 83% at 3 years vs. 30% standard
• "This is as good as any treatment we have seen in myeloma" - Dr. Luciano Costa, ASH 2025
• Presented ASH December 2025; Published NEJM February 2026; ASCO 2026
• FDA approval imminent / under review 2026
• Requires step-up dosing to mitigate CRS; ongoing infection risk due to immunosuppression

MajesTEC-9 Trial (ASCO 2026, published NEJM)

• Phase 3 RCT; n=593; RRMM at first relapse
• Teclistamab monotherapy vs. PVd or Kd (standard)
• Significant improvement in PFS, OS, MRD negativity
• Established teclistamab monotherapy as a new standard in first relapse (anti-CD38 + lenalidomide refractory population)

Other Approved Bispecifics:

• Elranatamab (BCMA × CD3): FDA approved 2023 in ≥4 prior lines; phase 3 ongoing
• Talquetamab (GPRC5D × CD3): FDA approved 2023; unique target (no overlap with BCMA)

5.4 BELANTAMAB MAFODOTIN (BELAMAF) - ANTI-BCMA ADC

DREAMM-7 (Hungria et al., NEJM 2024, PMID 38828933)

• Phase 3 RCT; n=494; RRMM after ≥1 prior line
• BVd (belantamab + bortezomib + dex) vs. DVd (daratumumab + bortezomib + dex)

• Ocular toxicity (keratopathy) is the key limiting toxicity; managed with dose modifications and ophthalmic monitoring
• BVd superior to DVd - but ocular toxicity requires specialist ophthalmology co-management

DREAMM-8 (Dimopoulos et al., NEJM 2024, PMID 38828951)

• Phase 3 RCT; n=302; lenalidomide-exposed RRMM
• BPd (belantamab + pomalidomide + dex) vs. PVd

• Belamaf was previously withdrawn but DREAMM-7 & 8 results led to FDA re-approval in 2024

---

6. TRIPLE-CLASS/HEAVILY PRETREATED RRMM (≥3-4 prior lines)

Standard Approved Options

CAR-T vs. Bispecific Antibody: 2026 Sequencing

---

7. COMPLETE TRIAL TIMELINE - LANDMARK TO LATEST

ERA 1: Chemotherapy Foundation (1962-1996)

ERA 2: IMiDs and Novel Agents (2003-2010)

ERA 3: Triplets and Maintenance (2010-2017)

ERA 4: Anti-CD38 Quadruplets and Frontline Transformation (2019-2024)

ERA 5: Immunotherapy Revolution and MRD-Guided Therapy (2025-2026)

---

8. DRUG DOSING QUICK REFERENCE

Frontline (Transplant-Eligible) - D-VRd (PERSEUS)

Frontline (Transplant-Ineligible) - D-Rd (MAIA)

Relapsed - Teclistamab (Step-up dosing)

---

9. MAINTENANCE THERAPY SUMMARY

---

10. HIGH-RISK MYELOMA: SPECIAL CONSIDERATIONS

---

11. SUMMARY TABLE - STANDARD OF CARE BY SETTING (2026)

---

REFERENCES

1. Goldman-Cecil Medicine, Chapter on Multiple Myeloma (GRIFFIN, MAIA, CASSIOPEIA references)
2. Sonneveld P et al., NEJM 2024 - PERSEUS trial D-VRd TE-NDMM (PMID 38084760)
3. Facon T et al., NEJM 2024 - IMROZ trial Isa-VRd TI-NDMM (PMID 38832972)
4. Facon T et al., Leukemia 2025 - MAIA 5-year update (PMID 40016302)
5. Usmani SZ et al., Nat Med 2025 - CEPHEUS trial D-VRd TI/deferred NDMM (PMID 39910273)
6. Leleu X et al., Nat Med 2024 - BENEFIT trial Isa-VRd vs Isa-Rd (PMID 38830994)
7. San-Miguel J et al., NEJM 2023 - CARTITUDE-4 cilta-cel (PMID 37272512)
8. Rodriguez-Otero P et al., NEJM 2023 - KarMMa-3 ide-cel (PMID 36762851)
9. Costa LJ et al., NEJM 2026 - MajesTEC-3 teclistamab + dara (PMID 41363801)
10. Hungria V et al., NEJM 2024 - DREAMM-7 BVd vs DVd (PMID 38828933)
11. Dimopoulos MA et al., NEJM 2024 - DREAMM-8 BPd vs PVd (PMID 38828951)
12. Dimopoulos MA et al., NEJM 2025 - AQUILA daratumumab in SMM (PMID 39652675)
13. Perrot A et al., NEJM 2025 - MIDAS MRD-guided therapy (PMID 40459097)
14. MajesTEC-9 Phase 3 trial - ASCO 2026 / NEJM 2026 (teclistamab vs PVd/Kd at first relapse)

---

Multiple Myeloma - Introduction, Classification, Clinical Features & Diagnosis

---

1. INTRODUCTION AND DEFINITION

1. Clonal bone marrow plasma cells ≥10% (or biopsy-proven plasmacytoma)
2. M-protein in serum or urine (except in non-secretory myeloma)
3. At least one myeloma-defining event (MDE) - either CRAB criteria or SLiM biomarkers

• Goldman-Cecil Medicine, Chapter 173

---

2. EPIDEMIOLOGY

• Annual incidence: ~4 per 100,000 in the US; approximately 35,000 new cases/year
• Peak age of onset: 65-70 years; median age at diagnosis ~70 years
• Male predominance (M:F ~1.4:1)
• Higher incidence in people of African descent - approximately 2× the incidence seen in Whites; also earlier age of onset
• MGUS prevalence by age (Mayo Clinic data):
  • Age 50-59: 1.2% (total population)
  • Age 70-79: 3.4%
  • Age 80+: 4.6%
  • African-Americans have significantly higher MGUS prevalence at all ages
• Robbins Pathology (Cotran), Chapter 13; Goldman-Cecil Medicine, p.1977

---

3. THE PLASMA CELL DYSCRASIA SPECTRUM (CLASSIFICATION)

Normal Plasma Cells → MGUS → Smoldering MM → Active MM → Plasma Cell Leukemia

3.1 Full Classification Table (IMWG Diagnostic Criteria)

• Goldman-Cecil Medicine, Table 173-2

3.2 Myeloma-Defining Events (MDE)

• C - hyperCalcemia: serum calcium >2.75 mmol/L (>11 mg/dL) OR >1 mg/dL above upper limit of normal
• R - Renal insufficiency: creatinine >177 µmol/L (>2 mg/dL) OR creatinine clearance <40 mL/min
• A - Anemia: Hgb <100 g/L (10 g/dL) OR >20 g/L below normal
• B - Bone lesions: one or more osteolytic lesions on skeletal survey, CT, or PET/CT

• SiXty percent: clonal bone marrow plasma cells ≥60%
• Light chain ratio: involved/uninvolved sFLC ratio ≥100
• MRI: >1 focal marrow lesion ≥5 mm on MRI

3.3 WHO/ICC 2022 Cytogenetic-Based Classification

1. MM with CCND family translocation - t(11;14) and t(6;14) - cyclin D1/D3
2. MM with NSD2 translocation - t(4;14) - NSD2/FGFR3
3. MM with MAF family translocation - t(14;16) and t(14;20)
4. MM with hyperdiploidy - trisomies of odd chromosomes (3, 5, 7, 9, 11, 15, 19, 21)
5. MM, NOS

• Quick Compendium of Clinical Pathology, section 4.3.7.3

---

4. PATHOGENESIS

4.1 Cell of Origin

4.2 Oncogenesis: Two Pathways

1. IgH translocations (~40%): Chromosomal translocations involving the IgH locus (14q32) juxtaposing oncogenes near the IgH enhancer. Key partners:
   • t(11;14): cyclin D1 - most common; standard-risk
   • t(4;14): NSD2/FGFR3 - high-risk
   • t(14;16): c-MAF - high-risk
   • t(14;20): MAFB - high-risk
   • t(6;14): cyclin D3 - standard-risk
2. Hyperdiploidy (~40%): Trisomies of odd-numbered chromosomes; generally standard-risk; associated with lower IgH translocation frequency
3. Both (~15%); Other (~5%)

• RAS mutations (KRAS, NRAS) - most common acquired mutation
• MYC rearrangements - associated with aggressive/extramedullary disease
• del(17p) - TP53 deletion; high-risk; associated with poor prognosis
• del(1p) - CDKN2C
• amp(1q) - CKS1B; high-risk; adverse outcome

4.3 Role of the Bone Marrow Microenvironment

• IL-6 (most important growth/survival cytokine): produced by tumor cells AND marrow stromal cells; high IL-6 = poor prognosis
• VEGF: promotes angiogenesis in marrow
• Direct stromal contact: VLA-4 integrin on myeloma cells binds VCAM-1 on stromal cells → NF-κB activation → survival
• NF-κB pathway: Frequently mutated in myeloma; promotes anti-apoptotic signals (Bcl-2, Bcl-XL)

4.4 Bone Disease Mechanism

• ↑ RANKL (receptor activator of NF-κB ligand) on osteoblasts and possibly plasma cells
• ↓ Osteoprotegerin (OPG) - RANKL decoy receptor
• ↑ MIP-1α (CCL3) - chemokine augmenting osteoclast formation
• ↑ IL-1β, IL-6, IL-3

• ↑ DKK1 (Dickkopf-1) - Wnt pathway inhibitor
• ↑ IL-3, IL-7

• Goldman-Cecil Medicine, p.1977-1978; Robbins & Cotran Pathology, p.568-569

---

5. MORPHOLOGY AND HISTOPATHOLOGY

5.1 Bone Marrow Aspirate

• Eccentric nucleus (clock-face/cartwheel chromatin)
• Perinuclear clearing (Hof) due to prominent Golgi apparatus
• Basophilic cytoplasm (high RNA content for Ig synthesis)

• Plasmablasts: large, vesicular nucleus, prominent single nucleolus - aggressive
• Flame cells: fiery red cytoplasm
• Mott cells: multiple grapelike cytoplasmic droplets (Russell bodies)
• Russell bodies: cytoplasmic globular inclusions of precipitated Ig
• Dutcher bodies: intranuclear Ig inclusions
• Multinucleated forms: bizarre giant plasma cells

5.2 Plasma Cell Percentage

• In 96% of myeloma, clonal plasma cells are ≥10% of nucleated BM cells
• In 4%, BM plasma cells may be <10% even with frank myeloma (focal disease) - repeat biopsy or lesion biopsy may be needed
• Diagnosis requires ≥10% clonal plasma cells, not just >10% plasma cells (exclude reactive plasmacytosis)

5.3 Bone Disease - Radiological Appearance

• Robbins & Cotran Pathology, p.569-570

---

6. CLINICAL FEATURES

6.1 Presenting Symptoms

• Bone pain in back or chest at diagnosis: >66% of patients
• Pathologic fractures (especially vertebral compression fractures)
• Height loss of several inches due to vertebral collapse
• Cord compression in up to 10% (thoracic > lumbosacral > cervical)

• Present in >70% at diagnosis
• Normocytic, normochromic
• Mechanism: marrow replacement by plasma cells, renal failure, direct inhibition of erythropoiesis by myeloma cytokines
• Presents as: weakness, fatigue, exertional dyspnea

• Renal insufficiency (creatinine >2 mg/dL) in ~20% at diagnosis
• Main mechanisms:
  1. Light chain cast nephropathy (myeloma kidney) - most common: free light chains precipitate in distal/collecting tubules forming large waxy laminated casts; severity correlates with urinary light chain load
  2. Hypercalcemia - leads to vasoconstriction, nephrogenic diabetes insipidus, reduced GFR
  3. AL amyloidosis (~10%): nephrotic syndrome + renal failure
  4. Light chain deposition disease: diffuse glomerular and tubular deposition
  5. Fanconi syndrome: proximal tubular dysfunction → glycosuria, phosphaturia, aminoaciduria
  6. Monoclonal gammopathy-associated proliferative GN

• Present in 15-20% at diagnosis
• Source: osteoclast-mediated bone destruction
• Symptoms: confusion, weakness, lethargy, constipation, polyuria, nausea, polydipsia ("stones, bones, groans, thrones, and psychiatric overtones")

• Recurrent bacterial infections (encapsulated organisms: Streptococcus pneumoniae, H. influenzae, Klebsiella)
• Mechanism: immunoparesis - suppression of normal immunoglobulin synthesis, neutropenia from marrow infiltration, impaired antibody responses
• Leading cause of death in myeloma (along with renal failure)

• Radiculopathy (thoracic > lumbosacral): most common neurological complication; vertebral collapse or plasmacytoma compressing nerve roots
• Spinal cord compression: emergency; occurs in ~10%
• Peripheral neuropathy: usually from AL amyloidosis; rarely direct myeloma neuropathy; also from bortezomib (treatment-related)
• Intracranial plasmacytomas: extensions of skull lesions
• CNS involvement: rare; very poor prognosis
• Hypercalcemia-related encephalopathy: confusion, lethargy, coma

• Visual disturbances (fundal changes: "sausage-link" retinal veins)
• Neurological symptoms
• Bleeding tendency

• Increased risk of deep vein thrombosis (especially with lenalidomide or thalidomide treatment)
• Occasionally: acquired factor inhibitors, platelet dysfunction from M-protein coating

• Hepatic infiltration
• Pleural effusions, ascites
• Multiple extramedullary plasmacytomas - sign of aggressive biology
• Plasma cell leukemia: >2×10⁹/L plasma cells in peripheral blood; very poor prognosis

6.2 Physical Examination Findings

• Rouleaux formation: red blood cells stacked in linear arrays like coins - due to high immunoglobulin levels coating RBCs; characteristic but not specific (also seen in SLE, early HIV)
• Normocytic normochromic anemia
• Rarely: circulating plasma cells (plasma cell leukemia)
• Goldman-Cecil Medicine, p.1979-1980; Robbins & Cotran Pathology, p.570

---

7. LABORATORY INVESTIGATION

7.1 Workup at Diagnosis

7.2 Protein Electrophoresis Explained

• Adding SPEP + serum IFE + serum FLC detects M-protein in nearly all cases of MM
• ~80% detected on SPEP alone
• ~2% of cases are non-secretory myeloma (no M-protein on SPEP/IFE/sFLC) - diagnosis by BM biopsy only

7.3 Immunophenotype by Flow Cytometry

• CD138+ (syndecan-1) - most specific marker
• CD38+ (strong) - the target for daratumumab and isatuximab
• CD45- (negative; distinguishes from normal plasma cells which are CD45+)
• CD56+ (aberrant expression; not on normal plasma cells)
• CD19- (negative; normal plasma cells are CD19-dim, myeloma cells CD19 absent)
• CD20+ in only ~20%
• Light chain restricted: either κ+ or λ+

• 4:1 → clonal κ population

• <1:2 → clonal λ population

7.4 Imaging in Multiple Myeloma

• Goldman-Cecil Medicine, p.1978-1979

---

8. STAGING

8.1 International Staging System (ISS) - Original

8.2 Revised ISS (R-ISS) - Current Standard

• Goldman-Cecil Medicine, Table 173-4

8.3 Cytogenetic Risk Stratification

---

9. DIAGNOSTIC CRITERIA SUMMARY (IMWG 2014)

Differential Diagnosis of Multiple Myeloma

---

10. RISK STRATIFICATION FOR MGUS PROGRESSION

1. M-protein ≥1.5 g/dL
2. Non-IgG subtype
3. Abnormal sFLC ratio

• 10% per year for first 5 years
• 5% per year for next 5 years
• 1-2% per year thereafter

• Risk approaches active myeloma within 2 years
• Now FDA-approved for treatment (daratumumab, AQUILA trial - November 2025)

---